Table 4. Clinical manifestations according to Stevens-Johnson syndrome and toxic epidermal necrolysis type.
| Characteristic | Total (n=92) | SJS (n=63) | SJS/TEN overlap (n=13) | TEN (n=16) | p value | |
|---|---|---|---|---|---|---|
| Age (yr) | 58.7±20.2 | 57.9±21.3 | 63.8±19.2 | 57.6±17.7 | 0.581 | |
| Female sex (%) | 43.5 | 42.9 | 53.8 | 37.5 | 0.878 | |
| Latent period (day) | 16.3±9.7 | 16.9±10.3 | 18.0±9.1 | 12.2±8.1 | 0.190 | |
| Culprit drug | ||||||
| Antibiotics | 28 | 16 | 6 | 6 | 0.210 | |
| Allopurinol | 20 | 16 | 2 | 2 | 0.219 | |
| Antiepileptics | 17 | 15 | 1 | 1 | 0.066 | |
| NSAIDs | 15 | 7 | 2 | 6 | 0.016* | |
| Acetaminophen | 2 | 1 | 1 | 0 | 0.984 | |
| Other drugs | 10 | 8 | 1 | 1 | 0.111 | |
| Medications number | 0.015* | |||||
| 1 | 74 (80.4) | 57 (90.5) | 5 (38.5) | 12 (75) | ||
| ≥2 | 18 (19.6) | 6 (9.5) | 8 (61.5) | 4 (25) | ||
| Route of administration | ||||||
| Oral | 69 (75.0) | 47 (74.6) | 10 (76.9) | 12 (75) | 0.938 | |
| IV or SC | 22 (23.9) | 15 (23.8) | 3 (23.1) | 4 (25) | 0.940 | |
| Eyedrop | 1 (1.1) | 1 (1.6) | 0 (0) | 0 (0) | 0.527 | |
| Duration of treatment (day) | 17.9±9.9 | 16.5±9.6 | 20.4±10.5 | 21.4±10.0 | 0.127 | |
| Clinical course | 0.142 | |||||
| Recovery | 84 (91.3) | 59 (93.7) | 12 (92.3) | 13 (81.3) | ||
| Death | 8 (8.7) | 4 (6.3) | 1 (7.7) | 3 (18.7) | ||
Values are presented mean ± standard deviation or number (%).
SJS, Stevens-Johnson syndrome; TEN, Toxic epidermal necrolysis; NSAIDs, nonsteroidal anti-inflammatory drugs; IV, intravenous; SC, subcutaneous.
*p < 0.05 was considered statistically significant.